SKYSTAR BIO-PHARMACEUTICAL COMPANY Inactive Instrument
Skystar Bio-Pharmaceutical Company Stock Nasdaq
Equities
US8308843007
Biotechnology & Medical Research
Financials (USD)
| Sales 2012 | 33.59M | Sales 2013 | 42.48M | Capitalization | 26.7M |
|---|---|---|---|---|---|
| Net income 2012 | 6M | Net income 2013 | 10M | EV / Sales 2012 | 0.2 x |
| Net cash position 2012 | 5.61M | Net Debt 2013 | 2.5M | EV / Sales 2013 | 0.69 x |
| P/E ratio 2012 |
1.93
x | P/E ratio 2013 |
2.56
x | Employees | - |
| Yield 2012 * |
-
| Yield 2013 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Tun Qu
BRD | Director/Board Member | 58 | 08-06-30 |
Skystar Bio-Pharmaceutical Co., Ltd. is a manufacturer and distributor of veterinary medicines and healthcare products in China. The Company develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine (TCM); topicals, supplements, probiotics, and diagnostic kits and animal, animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets within China. The Company operates four product lines: Probiotics, Veterinary Medicine, Veterinary Vaccines and Feed Additives. The Company provides a range of veterinary products serving regional micro-farms offering, such as Veterinary vaccines, including aquaculture, Veterinary medicines, Pro-biotic microorganisms and Animal feed additives. The Company's Veterinary drug products include Ivermectin Premix, Feizhu San, Tilmicosin Premix, Stimulated egg powder, Wulingsan, Yimu Shenghua San, Qingwen Baidu San and Spectinomycin Hydrochloride Injection.
| 1st Jan change | Capi. | |
|---|---|---|
| +26.28% | 42.68B | |
| -3.99% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +6.36% | 24.94B | |
| -21.47% | 18.96B | |
| +27.58% | 12.3B | |
| -2.75% | 11.95B | |
| -2.02% | 11.55B |
